Clinical pharmacology of modern antihypertensive agents and their interaction with a-adrenoceptor antagonists

British Journal of Urology

Volumn 81, Issue SUPPL. 1, 1998, Pages 6-16

  Narayan, P ^a   Man In't Veld, A J ^b,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FOSINOPRIL; IRBESARTAN; ISRADIPINE; LACIDIPINE; LISINOPRIL; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SPIRAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ANGIONEUROTIC EDEMA; ANKLE EDEMA; BRADYCARDIA; BRONCHOSPASM; CLINICAL PHARMACOLOGY; COMPARATIVE STUDY; CONSTIPATION; COUGHING; DRUG MECHANISM; FALLING; FATIGUE; FLUSHING; GINGIVA HYPERPLASIA; HEADACHE; HEART FAILURE; HEART PALPITATION; HUMAN; HYPOTENSION; IMPOTENCE; INSOMNIA; METABOLIC DISORDER; MOOD; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURFACE PROPERTY; TASTE DISORDER; VERTIGO;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG INTERACTIONS; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN; SULFONAMIDES;

EID: 0031857564     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1998.0810s1006.x     Document Type: Article

References (78)

1. Medical Research Council Working Party. MRC trial of mild hypertension: principal results. Lancet 1980; ii: 1261-7
2. Sever P. 1985, the year of hypertension trials: interpreting the results. Trends Pharmacol Sci; 1986; 6: 134-9
3. Roos JC, Boer P, Koomans HA. Geyskens GG, Dorhout Mees EJ. Haemodynamic and hormonal changes during acute and chronic diuretic treatment in essential hypertension. Eur J Clin Pharmacol 1981; 19: 107-12
4. Pandit MK, Burke J, Gustafson AB. Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Int Med 1993; 118: 529-39
5. Niarchos AP, Weinstein DL, Laragh JH. Comparison of the effects of diuretic therapy and low sodium intake in isolated systolic hypertension. Am J Med 1984; 77: 1061-8
6. Demartini FE, Wheaten EA, Healy LA, Laragh JH. Effect of chlorothiazide on renal excretion of uric acid. Am J Med 1962; 32: 572-6
7. Amery A. Berthaux P, Bulpitt C et al. Glucose intolerance during diuretic therapy. Lancet 1978; i: 681-3
8. Murphy MB, Lewis P J, Kohner E, Schumer B, Dollery CT. Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet 1982; ii: 1293-6
9. Gurwitz JH, Bohn RL. Glynn RJ, Monane M, Mogan H, Avorn J. Antihypertensive drug therapy and the initiation of treatment of diabetes mellitus. Ann Int Med 1992; 118: 273-8
10. Hollifleld JW. Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension. Am J Med 1984; 77: 28-32
11. Siegel D, Hulley SB, Black DM et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. J Am Med Assoc 1992: 267: 1083-9
12. Hoes AW, Grobbee DE, Peet TM, Lubsen J. Do nonpotassium sparing diuretics increase the risk of sudden cardiac death in hypertensive patients? Recent evidence. Drugs 1994; 47: 711-33
13. 3 Siscovick DS. Raghunathan TE. Psaty BM et al. Diuretic therapy for hypertension and the risk on primary cardiac arrest. N Engl J Med 1994; 330: 1852-7
14. Hoes AW, Grobbee DE. Lubsen J, Man in't Veld A J, van der Does E, Hofman A. Diuretic, beta-blockers and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995; 123: 481-7
15. Grimm RH Jr, Leon AS, Hunnibghake DB. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med 1981; 94: 7-11
16. Mclnnes GT, Yeo WW, Ramsay LE. Moser M. Cardiotoxicity and diuretics: much speculation -little substance. 1 Hypertension 1992: 10: 317-35
17. Heidland VA. Klütsch K. Öbek A. Myogenbedingte Vasodilatation bei Nierenischämie. Mönch Med Wochenschr 1962: 35: 1636-7
18. Clozel JP, Osterrieder W. Kleinbloesem CH et al. Ro 40-5967: a new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991; 9: 4-17
19. Opie LH. Calcium channel antagonists part I. fundamental properties: mechanisms, classification, sites of action. Cardiovasc Drugs Ther 1987; 1: 411-30
20. Wysocki M. Persson B. Bagge IJ, Andersson OK. Flow resistance and its components in hypertensive men treated with the calcium antagonist isradipine. Eur J Clin Pharmacol 1992; 43: 463-8
21. Christensen CK, Lederballe-Pedersen 0. Mikkelsen E. Renal effects of acute calcium blockade with nifedipine in hypertensive patients receiving adrenoceptor blocking drugs. Clin Pharmacol Ther 1982; 32: 572-6
22. Romero J. Raij L, Granger JP, Ruilope LM, Rodicio JL. Multiple effects of calcium entry blockers on renal function in hypertension. Hypertension 1987; 10: 141-50
23. Wetzels JF, Wiltink PG, Hoitsma AJ, Huismans FT. Koene RA. Diuretic and natriuretic effects of nifedipine in healthy persons. Br J Clin Pharmacol 1988: 25: 547-53
24. Kaplan NM. Critical comment on recent literature. Age and the response to antihypertensive drugs. Am J Hypertens 1989; 2: 213-5
25. Staessen JA. Fagard R, Thijs L et al. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64
26. Carruthers SG, Freeman DJ. Bailey DG. Synergistic adverse hemodynamic interaction between oral verapamil and propranolol. Clln Pharmacol Ther 1989; 46: 469-77
27. Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol 1987; 10 (Suppl 1): S121-S131
28. Ellis JS. Seymour RA, Monkman SC. Idle Gingival sequestration of nifedipine in nifedipine-induced gingival overgrowth. Lancet 1992: 339: 1382-3
29. Ondetti MA. Rubin B. Cushman DW. Design of specific inhibitors of angiotensin converting enzyme; a new class of orally active antihypertensive agents. Science 1977; 196: 441-4
30. Zimmerman BG, Sybert EG. Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984; 2: 581-8
31. Bao G, Gohlke P, Oadri F, Linger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 1992; 20: 74-9
32. Materson BJ, Reda DJ, Cushman WS et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328:914-21
33. Pannier B, Carabedian VG. Madonna O et al Lisinopril versus atenolol: decrease in systolic versus diatolic blood pressure with converting enzyme inhibition. Carrfiowisr Drugs Ther 1991: 5: 775-82
34. Hricik DE, Browning J. Kopelman R. Goorno WE. Madias NE. Dzau Vf. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery-stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 1983; 308: 373-6
35. Devoy MAB. Tomsom CRV. Edmunds ME. Feehally J, Walls J. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 1992; 232: 493-8
36. Perry IJ. Beevers DG. ACE inhibitors compared with thiazide diuretics as first-step antihypertensive therapy. Cardiovasc Drugs Ther 1989; 3: 815-9
37. Lewis EJ. Hunsicker LG. Bain RP, Rohde RD, for the collaborative Study Group. The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
38. MacFayden RJ. Lees KR. Reid JL. Differences in the first dose response to ACE inhibition in congestive heart failure -a placebo-controlled study. Er Heart J 1991: 69: 293-7
39. Webster J. Angiotensin converting enzyme inhibitors in the clinic: First dose hypotension. J Hypertension 1987: 5: S27-S30
40. Postma CT, Dennesen PJW, de Boo T, Thien T. First dose hypotension after captopril: can it be predicted? J Human Hypertension 1992; 6: 205-9
41. PDA (Food and Drug Administration). Health and Human Services News. Pregnancy warnings strengthened on ACE inhibitors. 13 March 1992
42. Yeo WW. MacLean D, Richardson PJ. Ramsay LE. Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double-blind conditions. Br J Clin Pharmacol 1991; 31: 356-9
43. Abu-Hadan DK. Desai H. Sonheimer J, Felicetta J. Mahajan S. McDonald F. Taste acuity and zinc metabolism in captopril-treated hypertensive male patients. Am J Hypertens 1988; 1: 303S-308S
44. Timmermans PBMWM, Wong PC. Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993: 45: 205
45. Goldberg MR. Tanak W. Barchowsky A et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993: 21: 704-13
46. van den Meiracker AH, Admiraal PJ, Jansen JA et al. Hemodynamic and biochemical effects of the AT,-receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22-9
47. Tsunoda K. Abe K. Hagino T et al. Hypertensive effects of losartan. a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993: 6: 2832
48. Tikkanen I. Omvik P, Jensen E. Comparison of angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertension 1995: 13: 1343-51
49. Weber MA, Byny RL, Pratt JH et al Blood pressure effects of the angiotensin II blocker, losartan. Arch Int Med 1995: 155: 405-11
50. Brent R, Beckman DA. Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clinical teratology counselers, Teratology 1991; 43: 543-6
51. Goldberg AI, Dunlay ML, Swet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995: 75: 793-5
52. Lacourciere Y, Brunner H, Irwin R et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387-93
53. Prichard BNC. Hypotensive action of pronethalol. Br MedJ 1964: 1: 1227-8
54. Prichard BNC, Gillam PMC. Treatment of hypertension with propranolol. Br MedJ 1969; 1: 7-10
55. McDevitt DG, Brown HC, Carruthers SG, Shanks RG. Influence of intrinsic sympathicomimetic activity and cardioselectivity on beta-adrenoceptor blockade. Clin Pharm Ther 1977; 2: 556-66
56. Man in't Veld AJ, Schalekamp MADH. Effects of 10 different beta-adrenoceptor antagonists on hemodynamics, plasma renin activity and plasma norepinephrine in hypertension: the key role of vascular resistance changes in relation to partial agonist activity. J Cardiovasc Pharmacol 1983; 5: S30-S45
57. van den Meiracker AH, Man in't Veld AJ, Ritsema van Eck HJ, Boomsma F, Schalekamp MADH. Hemodynamic and hormonal adaptions to beta-adrenoceptor blockade. A 24-hour study of acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. Circulation 1988; 78: 957-68
58. Lund-Johansen P. Omvik P. Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha-blockers and different types of beta-blockers with and without vasodilating effects. Cardiovasc Drugs Ther 1991; 5: 605-16
59. Man in't Veld AJ, van den Meiracker AH. Schalekamp MADH. Do beta-blockers really increase peripheral vascular resistance? Review of literature and new observations under basal conditions. Am J Hypertension 1988; 1: 91-6
60. van den Meiracker AH, Man in't Veld AJ, Boomsma F et al. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol and propranolol in hypertensive patients. Circulation 1989: 80: 903-14
61. Vyssoullis GP, Karpanou EA, Pitsavos CE, Skoumas JN, Paleologus AA, Toutouzas PK. Differentiation of betablocker effects on serum lipids and apolipoproteins in hypertensive patients with normolipidaemic or dyslipidaemic profiles. Eur Heart J 1992; 13: 1506-13
62. Zacest R. Gilmore E, Koch-Weser J. Treatment of essential hypertension with combined vasodilation and betaadrenergic blockade. N Engl J Med 1992: 286: 617-22
63. Murphy MB, Scriven AJI, Dollery CT. Role of nifedipine in treatment of hypertension. Br MedJ 1983; 287: 257-9
64. Decalmer PBS, Chattarjee SS, Cruickshank JM, Benson MK, Sterling GM. Beta-blockers and asthma. Br Heart J 1978; 40: 184-9
65. Fodor JG, Chockalingam A, Drover A. Fifield F, Pauls CJ. A comparison of the side effects of atenolol and propranolol in the treatment of patients with hypertension. J Clin Pharmacol 1987; 27: 892-901
66. Vanhoutte PM. Ball SG. Bordeaux A et al Mechanism of action of ketanserin in hypertension. Trends Pharmacol Sci 1986; 10 (Suppl 3): S1-S137
67. Van Zwieten PA, De Jonge A, Wilffert B. Timmermans PBMWM, Beckeringh JJ, Thoolen MJMC. Cardiovascular effects and interaction with adrenoceptors of urapidil. Arch Int Pharmacodyn 1985; 276: 180-201
68. Amery A. Treatment of hypertension with urapidil. Preclinical and clinical update. Roy Soc Med Serv 1986; 101: 1-186
69. Lithell H. Insulin resistance and cardiovascular drugs. Clin Exp Uypertens 1992: A14: 151-62
70. Pool JL. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Am HeartJ 1991; 121: 251-60
71. Ferrara LA, Di Marino L. Russo 0, Marotta T, Mancini M. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The doxazosin-captopril in hypercholesterolemic hypertensives study. Hypertension 1993; 5: 39-43
72. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant ot,-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995: 288: 201-7
73. Michel MC, Grübbel B, Taguchi K, Verfürth F. Otto T. Kröpfl D. Drugs for treatment of benign prostatic hyperplasia: Affinity comparison at cloned aradrenoceptor subtypes and in human prostate. J Auton Pharmacol 1996: 16: 21-8
74. Yamada S, Suzuki M. Tanaka C et al. Comparative study on alphal-adrenoceptor antagonist binding in human prostate and aorta. Clin Exp Pharmacol Physiol 1994; 21:405-11
75. Chappie CR, Wyndaele JJ. Nordling J. Boeminghaus F. Ypma AFGVM, Abrams P. Tamsulosin, the first prostateselective alpha(lA)-adrenoceptor antagonist. Meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155-67
76. Harada K, Ohmori M, Fujimura A. Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular alpha 1-adrenoceptors in humans. Naunyn Schmiedeberg's Arch Pharmacol 1996; 354: 557-61
77. Michel MC. Schäfers RF, Fokuhl B, Wasmuth A, Schumacher H. Comparison of hemodynamic effects of tamsulosin (tarn) and terazosin (ter) in man. J Urol 1997; 157: 137(A537)
78. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997; 19: 730-42